In a regulatory filing, BioCryst (BCRX) noted that as previously announced, on February 28, Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals notified the company of his intention to resign from his employment with the company, effective April 9. On April 7, the board appointed Jon Stonehouse, the company’s Chief Executive Officer, to serve as interim Chief Financial Officer and Interim Principal Accounting Officer, the filing stated. The company has also hired a former public biotechnology company Chief Financial Officer as a financial consultant to support Mr. Stonehouse while the company continues its search for a new Chief Financial Officer, the filing noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst CFO Anthony Doyle Resigns Effective April 2025
- BioCryst CFO Anthony Doyle to resign, effective April 9
- BioCryst’s Earnings Call Highlights Strong Growth and Future Prospects
- BioCryst’s Promising Outlook: Buy Rating Affirmed Amid Strong Sales Guidance and Strategic Growth Initiatives
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue